These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17110119)

  • 1. On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor.
    Das T; Chakraborty S; Banerjee S; Venkatesh M
    Appl Radiat Isot; 2007 Mar; 65(3):301-8. PubMed ID: 17110119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
    Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
    Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
    Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
    Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
    [No Abstract]   [Full Text] [Related]  

  • 4. Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.
    Bakker WH; Breeman WA; Kwekkeboom DJ; De Jong LC; Krenning EP
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):265-71. PubMed ID: 17043624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
    Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
    Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: a comparison with 'in-situ' preparation at hospital radiopharmacy.
    Das T; Banerjee S; Shinto A; Kamaleshwaran KK; Sarma HD
    Curr Radiopharm; 2014; 7(1):12-9. PubMed ID: 24934713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of patient doses of (177)Lu-DOTA-TATE using indigenously produced (177)Lu: the Indian experience.
    Das T; Chakraborty S; Kallur KG; Venkatesh M; Banerjee S
    Cancer Biother Radiopharm; 2011 Jun; 26(3):395-400. PubMed ID: 21728843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT.
    Breeman WA; Chan HS; de Zanger RM; Konijnenberg MK; de Blois E
    Curr Radiopharm; 2016; 9(1):8-18. PubMed ID: 25771369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single vial kit formulation of DOTATATE for preparation of (177) Lu-labeled therapeutic radiopharmaceutical at hospital radiopharmacy.
    Mukherjee A; Lohar S; Dash A; Sarma HD; Samuel G; Korde A
    J Labelled Comp Radiopharm; 2015 Apr; 58(4):166-72. PubMed ID: 25765604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
    Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ¹⁷⁷Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay.
    Balter H; Victoria T; Mariella T; Javier G; Rodolfo F; Andrea P; Graciela R; Juan H; Eugenia de M; Patricia O
    Curr Radiopharm; 2016; 9(1):85-93. PubMed ID: 25771367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
    Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
    Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production logistics of 177Lu for radionuclide therapy.
    Pillai MR; Chakraborty S; Das T; Venkatesh M; Ramamoorthy N
    Appl Radiat Isot; 2003; 59(2-3):109-18. PubMed ID: 12941498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
    Wehrmann C; Senftleben S; Zachert C; Müller D; Baum RP
    Cancer Biother Radiopharm; 2007 Jun; 22(3):406-16. PubMed ID: 17651048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy.
    Banerjee S; Das T; Chakraborty S; Samuel G; Korde A; Srivastava S; Venkatesh M; Pillai MR
    Nucl Med Biol; 2004 Aug; 31(6):753-9. PubMed ID: 15246366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.
    Breeman WA; De Jong M; Visser TJ; Erion JL; Krenning EP
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):917-20. PubMed ID: 12677301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to Single Low-dose
    Wang H; Cheng Y; Zhang J; Zang J; Li H; Liu Q; Wang J; Jacobson O; Li F; Zhu Z; Chen X
    Theranostics; 2018; 8(12):3308-3316. PubMed ID: 29930731
    [No Abstract]   [Full Text] [Related]  

  • 18. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors.
    Limouris GS; Karfis I; Chatzioannou A; Paphiti MI; Lyra M; Gennatas K; Nikou G; Voros D; Pragulidis GP; Polydorou AA; Gouliamos A
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):551-8. PubMed ID: 23358409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate.
    Petrik M; Laznickova A; Laznicek M; Zalutsky MR
    Anticancer Res; 2007; 27(6B):3941-6. PubMed ID: 18225554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An estradiol-conjugate for radiolabelling with 177Lu: an attempt to prepare a radiotherapeutic agent.
    Banerjee S; Das T; Chakraborty S; Samuel G; Korde A; Venkatesh M; Pillai MR
    Bioorg Med Chem; 2005 Jul; 13(13):4315-22. PubMed ID: 15927837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.